EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Comparative outcomes of arterial bypass using the human acellular vessel and great saphenous vein in patients with chronic limb ischemia

Sebastian Cifuentes, Indrani Sen, Randall R DeMartino, Bernardo C Mendes, Fahad Shuja, Jill J Colglazier, Manju Kalra, Melinda S Schaller, Jonathan J Morrison, Todd E Rasmussen

Journal of Vascular Surgery · 2024

DOI: 10.1016/j.jvs.2024.05.012 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Vascular Surgery, 2024. Verfasst von Sebastian Cifuentes und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Saphenous Vein, Peripheral Arterial Disease, Vascular Patency, Amputation, Surgical. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Mayo Clinic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The Human Acellular Vessel (HAV) is a novel, off-the-shelf biologic conduit being evaluated for arterial reconstructions. Regulatory studies in peripheral arterial disease (PAD) to date have consisted of single-arm cohorts with no comparator groups to contrast performance against established standards. This study aimed to compare outcomes of the HAV with autologous great saphenous vein (GSV) in patients with advanced PAD undergoing infrageniculate bypass. METHODS: Patients with advanced PAD and no autologous conduit who underwent bypass with the 6-mm diameter HAV (Group 1; n = 34) (March 2021-February 2024) were compared with a multicenter historical cohort who had bypass with single-segment GSV (group 2; n = 88) (January 2017-December 2022). The HAV was used under an Investigational New Drug protocol issued by the Food and Drug Administration (FDA) under the agency's Expanded Access Program. RESULTS: Demographics were comparable between groups (mean age 69 ± 10 years; 71% male). Group 1 had higher rates of tobacco use (37 pack-years vs 28 pack-years; P = .059), coronary artery disease (71% vs 43%; P = .007), and prior coronary artery bypass grafting (38% vs 14%; P = .003). Group 1 had more patients classified as wound, ischemia, and foot infection clinical stage 4 (56% vs 33%; P = .018) and with previous index leg revascularizations (97% vs 53%; P < .001). Both groups had a similar number of patients with chronic limb-threatening ischemia (Rutherford class 4-6) (88% vs 86%; P = .693) and Global Anatomic Staging System stage III (91% vs 96%; P = .346). Group 1 required a composite conduit (two HAV sewn together) in 85% of bypasses. The tibial vessels were the target in 79% of group 1 and 100% of group 2 (P < .001). Group 1 had a lower mean operative time (364 minutes vs 464 minutes; P < .001). At a median of 12 months, major amputation-free survival (73% vs 81%; P = .55) and overall survival (84% vs 88%; P = .20) were comparable. Group 1 had lower rates of primary patency (36% vs 50%; P = .044), primary-assisted patency (45% vs 72%; P = .002), and secondary patency (64% vs 72%; P = .003) compared with group 2. CONCLUSIONS: Implanted under Food and Drug Administration Expanded Access provisions, the HAV was more likely to be used in redo operations and cases with more advanced limb ischemia than GSV. Despite modest primary patency, the HAV demonstrated resilience in a complex cohort with no autologous conduit options, achieving good secondary patency and providing major amputation-free survival comparable with GSV at 12 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Saphenous VeinPeripheral Arterial DiseaseVascular PatencyAmputation, SurgicalChronic Limb-Threatening IschemiaHumansFemaleMaleAgedMiddle AgedTime FactorsRetrospective StudiesTreatment OutcomeLimb SalvageBlood Vessel ProsthesisBlood Vessel Prosthesis ImplantationRisk FactorsPostoperative Complications

Stichwörter der Autor:innen

Arterial occlusive diseaseBypassChronic limb-threatening ischemiaSaphenous veinTissue-engineered vascular graft

Autor:innen und Institutionen

  • Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN.
  • Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN. Electronic address: rasmussen.todd@mayo.edu.

Förderung

  • Mayo Clinic

Zitieren

APA

Cifuentes, S., Sen, I., DeMartino, R. R., Mendes, B. C., Shuja, F., Colglazier, J. J., Kalra, M., Schaller, M. S., Morrison, J. J., & Rasmussen, T. E. (2024). Comparative outcomes of arterial bypass using the human acellular vessel and great saphenous vein in patients with chronic limb ischemia. Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2024.05.012

Vancouver

Cifuentes S, Sen I, DeMartino RR, Mendes BC, Shuja F, Colglazier JJ, et al. Comparative outcomes of arterial bypass using the human acellular vessel and great saphenous vein in patients with chronic limb ischemia. Journal of Vascular Surgery. 2024. doi:10.1016/j.jvs.2024.05.012

BibTeX
@article{Cifuentes2024,
  author = {Cifuentes, Sebastian and Sen, Indrani and DeMartino, Randall R and Mendes, Bernardo C and Shuja, Fahad and Colglazier, Jill J and Kalra, Manju and Schaller, Melinda S and Morrison, Jonathan J and Rasmussen, Todd E},
  title = {Comparative outcomes of arterial bypass using the human acellular vessel and great saphenous vein in patients with chronic limb ischemia},
  journal = {Journal of Vascular Surgery},
  year = {2024},
  doi = {10.1016/j.jvs.2024.05.012}
}
Kostenlos starten →